Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
A New Approach to Test Validity and Clinical Usefulness of the 2013 Acc/Aha Guideline on Statin Therapy: A Population-Based Study Publisher Pubmed



Khalili D1, 2 ; Asgari S1 ; Hadaegh F1 ; Steyerberg EW3 ; Rahimi K4 ; Fahimfar N5 ; Azizi F6
Authors

Source: International Journal of Cardiology Published:2015


Abstract

Background: The ACC/AHA released a new guideline onthe assessment of cardiovascular risk and management of hypercholesterolemia that some controversy exists concerning its usefulness. We examined the clinical usefulness of this guideline in a high incidence population using novel measures. Methods: First, we validated the new risk equation in a cohort of 2372 men and 2781 women aged 40-75 years. Then, high risk individuals for cardiovascular diseases (CVDs) were identified according to the ACC/AHA guideline at baseline (as a predictor) and CVD outcomes were detected during a 10-year follow-up. Discrimination of the guideline was quantified and the quality of decisions was evaluated by Net Benefit Fraction index considering the harm, for false-positive, and benefit, for true-positive predictions. Finally, net number needed to treat (NNT) for statin was estimated, using test tradeoff index, in diabetic and non-diabetic subjects. Results: During follow-up, 726 CVD events including 298 hard CVDs occurred. The equation overestimated the risk by 57% in men and 48% in women. Based on the guideline, 73% of men and 44% of women were eligible for statin therapy. The lowest sensitivity was detected for intensive treatment in non-diabetic subgroups (82% in men and 41% in women; corresponding specificity, 52% and 90% respectively). The guideline had a significant net benefit for both moderate and intensive treatment, which resulted in estimated NNTs ranged 5-55; however, net benefit of intensive therapy was uncertain in non-diabetic women. Conclusions: We objectively showed that the ACC/AHA recommendations could be useful in our population but with some overtreatment in women. © 2015 Elsevier Ireland Ltd. All rights reserved.
Related Docs
View other Related Docs
1. Prediction of Cardiovascular Disease Mortality in a Middle Eastern Country: Performance of the Globorisk and Score Functions in Four Population-Based Cohort Studies of Iran, International Journal of Health Policy and Management (2022)
2. Risk of Coronary Heart Events Based on Rose Angina Questionnaire and Ecg Besides Diabetes and Other Metabolic Risk Factors: Results of a 10-Year Follow-Up in Tehran Lipid and Glucose Study, International Journal of Endocrinology and Metabolism (2017)
3. Performance of the Revised World Health Organization Cardiovascular Disease Risk Prediction Models for the Middle East and North Africa: A Validation Study in the Tehran Lipid and Glucose Study, Journal of Clinical Epidemiology (2025)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Mansournia (6)
Noushin Fahimfar (4)
Other Related Docs
4. An Office-Based Cardiovascular Prediction Model Developed and Validated in Cohort Studies of a Middle-Income Country, Journal of Clinical Epidemiology (2022)
5. Serum Alkaline Phosphatase and the Risk of Coronary Heart Disease, Stroke and All-Cause Mortality: Tehran Lipid and Glucose Study, BMJ Open (2018)
6. The Risk and Added Values of the Atherosclerotic Cardiovascular Risk Enhancers on Prediction of Cardiovascular Events: Tehran Lipid and Glucose Study, Journal of Translational Medicine (2021)
7. Evaluation of the Hypercholesterolemia Care Cascade and Compliance With Ncep-Atp Iii Guidelines in Iran Based on the Who Steps Survey, Lipids in Health and Disease (2025)
8. Sex-Specific Impact of Metabolic Dysfunction-Associated Fatty Liver Disease on Incident Cardiovascular Diseases and Mortality, Endocrinology, Diabetes and Metabolism (2025)
9. Population Attributable Fraction Estimates of Cardiovascular Diseases in Different Levels of Plasma Total Cholesterol in a Large-Scale Cross-Sectional Study: A Focus on Prevention Strategies and Treatment Coverage, Journal of Diabetes and Metabolic Disorders (2020)
10. Ldl-Cholesterol Measurement in Diabetic Type 2 Patients: A Comparison Between Direct Assay and Popular Equations, Journal of Diabetes and Metabolic Disorders (2017)
11. Trend of Cardiovascular Risk Factors in the Older Iranian Population: 2002–2014, Geriatrics and Gerontology International (2018)
12. Non-Invasive Risk Prediction Models in Identifying Undiagnosed Type 2 Diabetes or Predicting Future Incident Cases in the Iranian Population, Archives of Iranian Medicine (2019)
13. Mean Versus Variability of Lipid Measurements Over 6 Years and Incident Cardiovascular Events: More Than a Decade Follow-Up, Frontiers in Cardiovascular Medicine (2022)
14. Blood Pressure and Cardiovascular Morbidity Risk in Type 2 Diabetes With Hypertension Over a Decade of Follow-Up: Evidence for J-Shaped Phenomenon, Journal of Human Hypertension (2017)
15. External Validation of the European Risk Assessment Tool for Chronic Cardio-Metabolic Disorders in a Middle Eastern Population, Journal of Translational Medicine (2020)
16. Impact of 3-Year Changes in Lipid Parameters and Their Ratios on Incident Type 2 Diabetes: Tehran Lipid and Glucose Study, Nutrition and Metabolism (2018)
17. Validation of the Framingham Hypertension Risk Score in a Middle Eastern Population: Tehran Lipid and Glucose Study (Tlgs), BMC Public Health (2021)
18. Laboratory-Based and Office-Based Risk Scores and Charts to Predict 10-Year Risk of Cardiovascular Disease in 182 Countries: A Pooled Analysis of Prospective Cohorts and Health Surveys, The Lancet Diabetes and Endocrinology (2017)
19. Association Between Nontraditional Risk Factors and Calculated 10-Year Risk of Atherosclerotic Cardiovascular Disease in a Large General Population: Based on the Pars Cohort Study, Journal of Tehran University Heart Center (2023)
20. Menstrual Cycle Irregularity and Metabolic Disorders: A Population-Based Prospective Study, PLoS ONE (2016)